Primary hyperaldosteronism – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Primary hyperaldosteronism – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of baxdrostat compared to placebo to treat adults with primary aldosteronism https://clinicaltrials.eu/trial/study-of-baxdrostat-compared-to-placebo-to-treat-adults-with-primary-aldosteronism/ Wed, 29 Apr 2026 15:06:48 +0000 https://clinicaltrials.eu/trial/study-of-baxdrostat-compared-to-placebo-to-treat-adults-with-primary-aldosteronism/ This study focuses on Primary Aldosteronism, a condition where the body produces too much of a hormone called aldosterone. The study will test a medication called Baxdrostat (also known as CIN-107) to see how well it works and how safe it is for treating this condition. Primary Aldosteronism can cause high blood pressure and changes in blood potassium levels.

The study will compare Baxdrostat tablets with placebo in adults who have Primary Aldosteronism. During the study, participants will take either Baxdrostat or placebo orally each day. The medication dose may range from 2 to 4 milligrams per day. The main purpose is to determine if Baxdrostat can help lower blood pressure in people with this condition.

The treatment period will last for about one year (52 weeks). Throughout the study, participants will have their blood pressure monitored, and doctors will check various health measurements including hormone levels in blood and urine. The study will also track how the medication affects potassium levels in the blood.

]]> Study Comparing [68Ga]Ga-PentixaFor PET/CT and AVS for Diagnosing Primary Aldosteronism in Patients with Hypertension https://clinicaltrials.eu/trial/study-comparing-68gaga-pentixafor-pet-ct-and-avs-for-diagnosing-primary-aldosteronism-in-patients-with-hypertension/ Wed, 29 Apr 2026 15:01:07 +0000 https://clinicaltrials.eu/trial/study-comparing-68gaga-pentixafor-pet-ct-and-avs-for-diagnosing-primary-aldosteronism-in-patients-with-hypertension/ This clinical trial is focused on studying a condition known as Primary Aldosteronism, which is a type of hormonal disorder that can lead to high blood pressure. The study is comparing two different methods to diagnose and manage this condition. One method uses a special imaging technique called [68Ga]Ga-PentixaFor PET/CT, which involves a solution for injection that helps to highlight certain areas in the body during a scan. The other method is called AVS, which stands for Adrenal Vein Sampling, a procedure that measures hormone levels directly from the veins of the adrenal glands.

The purpose of the study is to see how well the [68Ga]Ga-PentixaFor PET/CT method works compared to the AVS method in identifying and understanding the condition. Participants in the study will be randomly assigned to either the PET/CT imaging or the AVS procedure. The study will follow participants for a period of time to observe the outcomes of each method, particularly focusing on how they affect blood pressure and overall health.

Throughout the study, researchers will also look at various factors such as the quality of the images produced by the PET/CT scans, the safety of the procedures, and the overall experience of the participants. The study aims to provide valuable information that could improve the diagnosis and treatment of Primary Aldosteronism in the future.

]]> Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism https://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-pet-imaging-for-identifying-unilateral-adrenal-aldosterone-secretion-in-patients-with-primary-aldosteronism/ Wed, 29 Apr 2026 14:47:44 +0000 https://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-pet-imaging-for-identifying-unilateral-adrenal-aldosterone-secretion-in-patients-with-primary-aldosteronism-2/ This clinical trial is focused on studying a condition known as Primary Aldosteronism, which is a disorder where the adrenal glands produce too much of a hormone called aldosterone. The study will use a special imaging technique called [68Ga]Ga-PentixaFor PET imaging to help identify whether the excess hormone production is coming from one or both adrenal glands. The treatment involves an injection of a solution containing Gallium (68Ga) and Pentixafor, which are substances that help in visualizing the adrenal glands during the imaging process.

The purpose of the study is to evaluate if this imaging method can effectively distinguish between patients with hormone production from one side of the adrenal glands versus both sides. Participants will receive the injection and undergo the PET imaging, which is a type of scan that helps doctors see how the adrenal glands are functioning. The study will monitor the effects of the injection and the imaging results to gather information on how well this method works in identifying the source of hormone production.

Throughout the study, the safety and tolerance of the [68Ga]Ga-PentixaFor injections will be closely observed. The study aims to provide valuable insights into the management of Primary Aldosteronism by potentially offering a new way to pinpoint the source of the problem, which could help in planning further treatment options for patients with this condition.

]]>